Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Hold” by Brokerages

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have earned an average recommendation of “Hold” from the ten brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $56.7143.

Several research analysts recently weighed in on IMCR shares. Zacks Research lowered shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Harbour Investments Inc. increased its holdings in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after acquiring an additional 388 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after purchasing an additional 572 shares in the last quarter. R Squared Ltd grew its position in shares of Immunocore by 7.4% in the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after purchasing an additional 606 shares during the period. Leonteq Securities AG acquired a new position in shares of Immunocore in the 4th quarter valued at approximately $30,000. Finally, Orion Porfolio Solutions LLC increased its stake in Immunocore by 4.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock worth $752,000 after purchasing an additional 1,031 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Stock Performance

NASDAQ:IMCR opened at $33.81 on Monday. Immunocore has a 1-year low of $27.56 and a 1-year high of $40.71. The business’s 50-day moving average price is $31.19 and its two-hundred day moving average price is $31.32. The company has a current ratio of 4.18, a quick ratio of 4.15 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -61.47 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.51. The company had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 EPS. On average, equities analysts expect that Immunocore will post 0.06 earnings per share for the current year.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.